

Supplementary Table 3. Baseline characteristics of the NSTEMI group stratified by the time to presentation

Characteristic	Early presenters		Late presenters		p value	p value (36–48 h vs. ≥ 48 h)
	< 24 h (n = 1,691)	24–36 h (n = 167)	36–48 h (n = 48)	≥ 48 h (n = 481)		
Male patients	1,145 (67.7)	89 (53.3)	32 (66.7)	304 (63.2)	0.041	0.634
Age, yr	65.59 ± 11.20	67.90 ± 10.18	66.19 ± 11.16	68.57 ± 10.58	< 0.001	0.140
Age ≥ 75 yr	396 (23.4)	51 (30.5)	15 (31.3)	159 (33.1)	< 0.001	0.800
EMS utilization	240 (14.2)	9 (5.4)	2 (4.2)	21 (4.4)	< 0.001	> 0.999
Killip III–IV	245 (14.5)	27 (16.2)	5 (10.4)	81 (16.8)	0.251	0.250
BMI ≥ 25 kg/m ²	598 (36.1)	51 (31.5)	15 (32.6)	175 (37.4)	0.741	0.521
Previous history						
Hypertension	1,107 (65.5)	128 (76.6)	31 (64.6)	342 (71.1)	0.016	0.345
DM	1,428 (84.4)	152 (91.0)	43 (89.6)	433 (90.0)	0.001	0.923
Dyslipidemia	252 (14.9)	26 (15.6)	5 (10.4)	78 (16.2)	0.570	0.292
Prior IHD	464 (27.4)	37 (22.2)	11 (22.9)	117 (24.3)	0.128	0.828
Prior CVA	169 (10.1)	20 (12.0)	9 (18.8)	51 (10.7)	0.444	0.097
Smoking	879 (53.4)	61 (37.4)	27 (56.3)	230 (49.1)	0.076	0.348
Family history of IHD	104 (6.3)	11 (6.9)	1 (2.1)	17 (3.7)	0.026	
LVEF, %	51.98 ± 12.23	52.19 ± 11.54	54.71 ± 9.92	50.14 ± 13.00	0.010	0.005
LVEF < 40%	257 (15.8)	24 (14.9)	4 (8.5)	99 (21.3)	0.013	0.036
Use of PCI	1,388 (82.1)	139 (83.2)	42 (87.5)	401 (83.4)	0.420	0.459
DBT strata, h					0.041	0.490
< 1.5	80 (5.8)	10 (7.2)	2 (4.8)	18 (4.5)		
1.5–24	933 (67.4)	87 (62.6)	29 (69.0)	255 (63.6)		
≥ 24	372 (26.9)	42 (30.2)	11 (26.2)	128 (31.9)		
Femoral approach	743 (53.5)	71 (51.1)	22 (52.4)	195 (48.6)	0.084	0.746
GPIIb/IIIa inhibitors	105 (7.6)	10 (7.2)	2 (4.8)	30 (7.5)	0.865	0.756
Thrombus aspiration	143 (10.3)	10 (7.2)	2 (4.8)	26 (6.5)	0.012	> 0.999
Image-guided PCI	338 (24.4)	36 (25.9)	13 (31.0)	82 (20.4)	0.169	0.115
IRA					0.196	0.142
LMCA	41 (3.0)	6 (4.3)	4 (9.5)	14 (3.5)		
LAD	566 (40.8)	57 (41.0)	9 (21.4)	192 (47.8)		
LCX	368 (26.6)	37 (26.6)	13 (31.0)	75 (18.7)		
RCA	411 (29.7)	39 (28.1)	16 (38.1)	121 (30.1)		
ACC/AHA lesion types					0.804	0.490
B2/C lesion	1,179 (85.1)	118 (84.9)	38 (90.5)	341 (84.8)		
A/B1 lesion	207 (14.9)	21 (15.1)	4 (9.5)	61 (15.2)		
Initial TIMI flow grade					0.734	0.466
0–I	498 (35.9)	46 (33.1)	17 (40.5)	140 (34.8)		
II–III	888 (64.1)	93 (66.9)	25 (59.5)	262 (65.2)		
LMCA disease	103 (6.3)	13 (7.9)	5 (11.1)	33 (7.1)	0.401	0.364
MVD	947 (57.6)	91 (55.2)	30 (66.7)	300 (64.2)	0.009	0.745

Supplementary Table 3. Continued

Characteristic	Early presenters		Late presenters		<i>p</i> value	<i>p</i> value (36–48 h vs. ≥ 48 h)
	< 24 h (n = 1,691)	24–36 h (n = 167)	36–48 h (n = 48)	≥ 48 h (n = 481)		
Use of thrombolysis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	-	-
Discharge medications						
Aspirin	1,680 (99.3)	166 (99.4)	48 (100.0)	476 (99.0)	0.437	> 0.999
P2Y12 inhibitors	1,671 (98.8)	163 (97.6)	47 (97.9)	477 (99.2)	0.673	0.380
Beta-blockers	1,411 (83.4)	136 (81.4)	42 (87.5)	399 (83.0)	0.862	0.420
RAS inhibitors	1,346 (79.6)	133 (79.6)	37 (77.1)	363 (75.5)	0.052	0.804
Statins	1,525 (90.2)	152 (91.0)	47 (97.9)	425 (88.4)	0.339	0.047

Values are presented as number (percentage) for categorical values and mean ± standard deviation for continuous variables.

ACC/AHA, American College of Cardiology/American Heart Association; BMI, body mass index; CVA, cerebrovascular accident; DBT, door-to-balloon time; DM, diabetes mellitus; EMS, emergency medical service; IHD, ischemic heart disease; IRA, infarct-related artery; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; LMCA, left main coronary artery; LVEF, left ventricular ejection fraction; MVD, multivessel disease; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; RAS, renin-angiotensin system; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.